Sodium-glucose cotransporter 2 inhibitors for treating diabetes mellitus.
作者信息
Goldberg Nicola, Fralick Michael
机构信息
Department of Medicine (Goldberg), University of Toronto, Toronto, Ont.; Division of Pharmacoepidemiology and Pharmacoeconomics (Fralick), Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Mass.; Division of General Internal Medicine (Fralick), Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Ont.
出版信息
CMAJ. 2017 May 23;189(20):E724. doi: 10.1503/cmaj.161455.
Abstract
摘要
相似文献
1
Sodium-glucose cotransporter 2 inhibitors for treating diabetes mellitus.用于治疗糖尿病的钠-葡萄糖协同转运蛋白2抑制剂。
CMAJ. 2017 May 23;189(20):E724. doi: 10.1503/cmaj.161455.
2
Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.钠-葡萄糖协同转运蛋白2抑制剂与糖尿病酮症酸中毒
J Diabetes. 2016 Mar;8(2):175-6. doi: 10.1111/1753-0407.12353. Epub 2015 Dec 29.
3
[Glucose renal excretion as diabetes treatment: From an old diagnostic method to a new way of treatment].[葡萄糖肾脏排泄作为糖尿病治疗方法：从一种古老的诊断方法到一种新的治疗方式]
Med Clin (Barc). 2016 May 20;146(10):460-4. doi: 10.1016/j.medcli.2015.12.003. Epub 2016 Jan 26.
4
Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.2017年的糖尿病肾病：糖尿病肾病治疗的新时代。
Nat Rev Nephrol. 2018 Feb;14(2):78-80. doi: 10.1038/nrneph.2017.182. Epub 2018 Jan 8.
5
Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India.2型糖尿病患者使用钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂相关的酮尿症/酮血症：来自印度新德里的三例报告
J Diabetes. 2016 Sep;8(5):738-9. doi: 10.1111/1753-0407.12411. Epub 2016 Jul 1.
6
Reduced Mortality With Sodium-Glucose Cotransporter-2 Inhibitors in Observational Studies: Avoiding Immortal Time Bias.观察性研究中钠-葡萄糖协同转运蛋白2抑制剂降低死亡率：避免不朽时间偏倚
Circulation. 2018 Apr 3;137(14):1432-1434. doi: 10.1161/CIRCULATIONAHA.117.032799.
7
Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.2型糖尿病老年患者中钠-葡萄糖协同转运蛋白2抑制剂的应用。
South Med J. 2015 Feb;108(2):91-6. doi: 10.14423/SMJ.0000000000000235.
8
[Introduction].[引言]
Med Clin (Barc). 2013 Sep;141 Suppl 2:1-2. doi: 10.1016/S0025-7753(13)70055-1.
9
Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂对血压的影响使其成为糖尿病合并高血压患者的一个有吸引力的选择。
J Am Soc Hypertens. 2016 Mar;10(3):186-7. doi: 10.1016/j.jash.2016.01.001.
10
Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.钠-葡萄糖协同转运蛋白2抑制：糖尿病治疗的新方法。
J Diabetes. 2013 Sep;5(3):225-7. doi: 10.1111/1753-0407.12065. Epub 2013 Jul 1.
本文引用的文献
1
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂对 2 型糖尿病成人患者心血管事件、死亡和主要安全性结局的影响：系统评价和荟萃分析。
Lancet Diabetes Endocrinol. 2016 May;4(5):411-9. doi: 10.1016/S2213-8587(16)00052-8. Epub 2016 Mar 18.
2
Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.与2型钠-葡萄糖协同转运蛋白（SGLT2）抑制剂的药物相互作用，这是用于治疗2型糖尿病的新型口服降糖药。
Clin Pharmacokinet. 2014 Apr;53(4):295-304. doi: 10.1007/s40262-013-0128-8.
3
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂治疗 2 型糖尿病：系统评价和荟萃分析。
Ann Intern Med. 2013 Aug 20;159(4):262-74. doi: 10.7326/0003-4819-159-4-201308200-00007.
Zotero 插件